Healthcare · Pharmaceuticals: Major

Regeneron Pharmaceuticals, Inc.

NASDAQREGN ISINUS75886F1075 SEC CIK0000872589 Listed on NASDAQ · USD

$953.01 -6.40 (-0.67%) Pre-market $972.29 (+1.34%) ≈ ₹89,442 a share

Open chart

Price, last 12 months+45.91% in a year

Key numbers

Market value: $98.59B
P/E (TTM): 21.1
Forward P/E: 12.3
EPS (TTM): $45.28
Dividend yield: 0.39%
Beta: 0.09
Day range: $950.21 – $981.55
52-week range: $591.52 – $991.73
Volume: 281,806
10-day avg volume: $1.31M
Revenue (TTM): $16.90B
EBITDA (TTM): $5.82B
Gross margin: 86.8%
Net margin: 28.5%
Return on equity: 15.0%
Debt / equity: 8.1%
Price / sales: 5.83
Shares out: 103.45M

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$3.43B$972.90M$1.16B

Dec 23

$3.15B$751.40M$722.00M

Mar 24

$3.55B$1.07B$1.43B

Jun 24

$3.72B$1.18B$1.34B

Sep 24

$3.79B$990.20M$917.70M

Dec 24

$3.03B$591.70M$808.70M

Mar 25

$3.68B$1.08B$1.39B

Jun 25

$3.75B$1.03B$1.46B

Sep 25

$3.88B$879.90M$844.60M

Dec 25

$3.61B$642.90M$727.20M

Mar 26

$4.29B$1.29B$1.30B

Jun 26

$5.12B$2.05B$1.95B

Sep 26

Revenue · QoQ (vs last quarter)

—-8.4%+13%+4.9%+1.8%-20%+21%+2.1%+3.5%-7.2%+19%+19%

Revenue · YoY (vs a year ago)

————+10%-3.7%+3.6%+0.9%+2.5%+19%+17%+36%

Net income · QoQ (vs last quarter)

—-38%+98%-6.4%-32%-12%+72%+4.9%-42%-14%+78%+50%

Net income · YoY (vs a year ago)

————-21%+12%-2.8%+8.9%-8.0%-10%-6.8%+33%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$3.43B	$3.15B	$3.55B	$3.72B	$3.79B	$3.03B	$3.68B	$3.75B	$3.88B	$3.61B	$4.29B	$5.12B
Research & development	$1.18B	$1.25B	$1.20B	$1.27B	$1.41B	$1.33B	$1.42B	$1.48B	$1.63B	$1.54B	$1.63B	$1.79B
Selling, general & admin	$737.70M	$689.00M	$758.80M	$714.40M	$792.20M	$633.00M	$634.20M	$657.80M	$775.00M	$647.70M	$662.10M	$677.80M
Operating income	$972.90M	$751.40M	$1.07B	$1.18B	$990.20M	$591.70M	$1.08B	$1.03B	$879.90M	$642.90M	$1.29B	$2.05B
Operating margin	28.3%	23.9%	30.2%	31.7%	26.1%	19.5%	29.4%	27.3%	22.7%	17.8%	30.1%	40.0%
Interest expense	$18.30M	$16.10M	$14.80M	$13.80M	$10.50M	$8.70M	$3.60M	$19.30M	$12.20M	$12.90M	$11.00M	$10.60M
Pre-tax income	$1.15B	$700.70M	$1.63B	$1.49B	$958.10M	$905.00M	$1.52B	$1.76B	$1.04B	$831.20M	$1.53B	$2.28B
Income tax	$-12.00M	$-21.30M	$195.80M	$152.40M	$40.40M	$96.30M	$127.10M	$303.30M	$199.10M	$104.00M	$230.90M	$335.40M
Net income	$1.16B	$722.00M	$1.43B	$1.34B	$917.70M	$808.70M	$1.39B	$1.46B	$844.60M	$727.20M	$1.30B	$1.95B
Net margin	33.8%	23.0%	40.4%	36.0%	24.2%	26.7%	37.9%	38.9%	21.7%	20.2%	30.2%	38.1%
EPS (diluted)	—	$6.27	$12.41	$11.54	—	$7.27	$12.81	$13.62	—	$6.75	$12.23	$18.45

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$5.15B$4.91B$2.44B

FY18

$6.56B$6.15B$2.12B

FY19

$8.50B$3.51B

FY20

$16.07B$8.08B

FY21

$12.17B$4.34B

FY22

$13.12B$3.95B

FY23

$14.20B$4.41B

FY24

$14.34B$4.50B

FY25

Revenue · YoY (vs a year ago)

—+27%+30%+89%-24%+7.8%+8.3%+1.0%

Net income · YoY (vs a year ago)

—-13%+66%+130%-46%-8.9%+12%+2.1%

RevenueGross profitNet incomeLine = trend

$21.29

FY18

$18.46

FY19

$30.52

FY20

$71.97

FY21

$38.22

FY22

$34.77

FY23

$38.34

FY24

$41.48

FY25

EPS (diluted) · YoY (vs a year ago)

—-13%+65%+136%-47%-9.0%+10%+8.2%

EPS (diluted)Line = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$5.15B	$6.56B	$8.50B	$16.07B	$12.17B	$13.12B	$14.20B	$14.34B
Revenue growth	—	27.4%	29.6%	89.1%	-24.3%	7.8%	8.3%	1.0%
Cost of revenue	$237.50M	$402.80M	—	—	—	—	—	—
Gross profit	$4.91B	$6.15B	—	—	—	—	—	—
Gross margin	95.4%	93.9%	—	—	—	—	—	—
Research & development	$1.47B	$2.45B	$2.65B	$2.86B	$3.59B	$4.44B	$5.13B	$5.85B
Selling, general & admin	$1.13B	$1.34B	$1.35B	$1.82B	$2.12B	$2.63B	$2.95B	$2.70B
Operating income	$2.53B	$2.21B	$3.58B	$8.95B	$4.74B	$4.05B	$3.99B	$3.58B
Operating margin	49.3%	33.7%	42.1%	55.7%	38.9%	30.9%	28.1%	24.9%
Depreciation & amortisation	$148.20M	$210.30M	$235.90M	$286.20M	$341.40M	$421.00M	$482.90M	$543.70M
Interest expense	$28.20M	$30.20M	$56.90M	$57.30M	$59.40M	$73.00M	$55.20M	$43.80M
Pre-tax income	$2.55B	$2.43B	$3.81B	$9.33B	$4.86B	$4.20B	$4.78B	$5.23B
Income tax	$109.10M	$313.30M	$297.20M	$1.25B	$520.40M	$245.70M	$367.30M	$725.80M
Tax rate	4.3%	12.9%	7.8%	13.4%	10.7%	5.9%	7.7%	13.9%
Net income	$2.44B	$2.12B	$3.51B	$8.08B	$4.34B	$3.95B	$4.41B	$4.50B
Net margin	47.5%	32.3%	41.3%	50.2%	35.6%	30.1%	31.1%	31.4%
EPS (diluted)	$21.29	$18.46	$30.52	$71.97	$38.22	$34.77	$38.34	$41.48

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$8.76B$2.81B

FY18

$11.09B$0$3.21B

FY19

$11.03B$1.98B$3.59B

FY20

$18.77B$1.98B$5.69B

FY21

$22.66B$1.98B$7.74B

FY22

$25.97B$1.98B$10.84B

FY23

$29.35B$1.98B$9.01B

FY24

$31.26B$1.99B$8.61B

FY25

Shareholders' equity · YoY (vs a year ago)

—+27%-0.6%+70%+21%+15%+13%+6.5%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & equivalents	$1.47B	$1.62B	$2.19B	$2.89B	$3.11B	$2.73B	$2.49B	$3.12B
Short-term investments	$1.34B	$1.60B	$1.39B	$2.81B	$4.64B	$8.11B	$6.52B	$5.49B
Current assets	$6.45B	$7.69B	$9.78B	$14.01B	$15.88B	$19.48B	$18.66B	$18.02B
Total assets	$11.73B	$14.81B	$17.16B	$25.43B	$29.21B	$33.08B	$37.76B	$40.56B
Current liabilities	$1.44B	$2.10B	$2.70B	$3.93B	$3.14B	$3.42B	$3.94B	$4.37B
Long-term debt	—	$0	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B	$1.99B
Total debt	—	$0	$1.98B	$1.98B	$1.98B	$1.98B	$1.98B	$1.99B
Total liabilities	$2.98B	$3.72B	$6.14B	$6.67B	$6.55B	$7.11B	$8.41B	$9.30B
Shareholders' equity	$8.76B	$11.09B	$11.03B	$18.77B	$22.66B	$25.97B	$29.35B	$31.26B
Current ratio	4.47	3.67	3.63	3.56	5.06	5.69	4.73	4.13
Debt / equity	—	0.00	0.18	0.11	0.09	0.08	0.07	0.06
Return on equity	27.9%	19.1%	31.9%	43.0%	19.1%	15.2%	15.0%	14.4%

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$2.20B$1.81B$4.40M

FY18

$2.43B$2.00B$275.90M

FY19

$2.62B$2.00B$5.85B

FY20

$7.08B$6.53B$1.65B

FY21

$5.01B$4.42B$2.08B

FY22

$4.59B$3.88B$2.24B

FY23

$4.42B$3.66B$2.60B

FY24

$4.98B$4.08B$3.81B

FY25

Operating cash flow · YoY (vs a year ago)

—+11%+7.7%+170%-29%-8.4%-3.8%+13%

Free cash flow · YoY (vs a year ago)

—+10%+0.2%+226%-32%-12%-5.4%+11%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash from operations	$2.20B	$2.43B	$2.62B	$7.08B	$5.01B	$4.59B	$4.42B	$4.98B
Capital spending	$-383.10M	$-429.60M	$-614.60M	$-551.90M	$-590.10M	$-718.60M	$-755.90M	$-898.40M
Free cash flow	$1.81B	$2.00B	$2.00B	$6.53B	$4.42B	$3.88B	$3.66B	$4.08B
FCF margin	35.2%	30.5%	23.6%	40.6%	36.3%	29.5%	25.8%	28.4%
Stock-based pay	$427.40M	$464.30M	$432.00M	$601.70M	$725.00M	$885.00M	$982.80M	$993.70M
Cash from investing	$-1.46B	$-2.03B	$-70.60M	$-5.38B	$-3.78B	$-3.19B	$-2.47B	$-629.10M
Cash from financing	$-77.10M	$-252.10M	$-1.97B	$-1.01B	$-1.01B	$-1.79B	$-2.20B	$-3.72B
Dividends paid	—	—	—	—	—	$0	$0	$-370.30M
Share buybacks	$-4.40M	$-275.90M	$-5.85B	$-1.65B	$-2.08B	$-2.24B	$-2.60B	$-3.44B

About

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Regeneron Pharmaceuticals, Inc.
Ticker: REGN
Exchange: NASDAQ
ISIN: US75886F1075
SEC CIK: 0000872589
Sector: Healthcare
Industry: Pharmaceuticals: Major
SEC industry (SIC): Pharmaceutical Preparations (2834)
Incorporated in: New York
Financial year ends: 31 December
Filer type: Large accelerated filer
Latest annual report (10-K): 4 Feb 2026
CEO: Leonard S. Schleifer
Chair: George D. Yancopoulos,Leonard S. Schleifer
Headquarters: Eastview
Address: 777 Old Saw Mill River Road, Tarrytown, Ny 10591
Founded: 1988
Employees: 15,410
Trades in: US dollars (USD)
Website: regeneron.com

News

Peers

Others in Healthcare

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Regeneron Pharmaceuticals, Inc.

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers